Know Cancer

or
forgot password

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer


Phase 1
18 Years
N/A
Not Enrolling
Both
Non-Small-Cell Lung Carcinoma

Thank you

Trial Information

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer


Inclusion Criteria:



- Subjects with advanced or metastatic non small cell lung cancer.

- Subjects should have had at least one prior chemotherapy with a platinum based
therapy.

Exclusion Criteria:

- Subjects are excluded from this study if they do not have non small cell lung cancer
that is advanced or metastatic or have not had at least one prior platinum based
chemotherapy.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safe and effective dose of combination of Erbitux and Iressa therapy.

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

United States: Food and Drug Administration

Study ID:

CA225-064

NCT ID:

NCT00162318

Start Date:

March 2005

Completion Date:

April 2006

Related Keywords:

  • Non-Small-Cell Lung Carcinoma
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Local InstitutionDuncansville, Pennsylvania